Duchenne Muscular Dystrophy Therapeutics Market, by Type (Pain Management Drugs, Corticosteroids, Prednisolone, Prednisone, Deflazacort) and, by End User (Hospitals, Clinics, Home Care Settings): Global Opportunity Analysis and Industry Forecast, 2023-2032

Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.

Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, low rate of treatment due to delayed diagnosis and prediction hinder the market growth. Moreover, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.

The global Duchenne muscular dystrophy therapeutics market is segmented on the basis of type, end user, and region. On the basis of type, it is bifurcated into pain management drugs and corticosteroids. Corticosteroids are further sub-segmented into prednisolone, prednisone, and deflazacort. On the basis of end-user, it is divided into hospitals, clinics, and home care settings. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key players in the market include Bristol-Myers Squibb Company, FibroGen, Inc., ITALFARMACO S.p.A., Marathon Pharmaceuticals, LLC, NS Pharma, Inc, PTC Therapeutics, Inc., Pfizer Inc., ReveraGen BioPharma, Inc., Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.

Key Benefits

• The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• Extensive analysis by product helps understand various therapeutics used for Duchenne dystrophy.
• Comprehensive analysis of all geographical regions is provided, which helps determine the prevailing opportunities.
• Key players are profiled and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market.

  Duchenne Muscular Dystrophy Therapeutics Market Report Highlights

Aspects	Details
By Type	Pain Management Drugs Corticosteroids Prednisolone Prednisone Deflazacort
By End User	Hospitals Clinics Home Care Settings
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	FibroGen, Inc., Marathon Pharmaceuticals, LLC, ITALFARMACO S.p.A., Pfizer Inc., Santhera Pharmaceuticals, Sarepta Therapeutics, Inc., PTC Therapeutics, Inc., ReveraGen BioPharma, Inc, NS Pharma, Inc, Bristol Myers Squibb Company

^*Terms and Conditions Apply